Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacologic maintenance strategies following allogeneic hematopoietic cell transplantation for acute myeloid leukemia.

Leukemia & lymphoma - 1 Mar 2017

Lee Catherine J, Shiraz Parveen, Muffly Lori

Abstract excerpt

The use of pharmacologic agents to maintain remission following allogeneic hematopoietic cell transplantation (HCT) is a topic of increasing interest and exploration for patients with high-risk acute myeloid leukemia (AML). This review details published and ongoing studies focused on post-transplant pharmacologic maintenance for AML. While early phase studies have demonstrated the safety and tolerability of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clinical Trials as Topic
Share to Combined Modality Therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to fms-Like Tyrosine Kinase 3

Share to Hematopoietic Stem Cell Transplantation

Share to Leukemia, Myeloid, Acute

Share to Maintenance Chemotherapy

Share to Molecular Targeted Therapy

Share to Transplantation, Homologous

Source

Identifiers

PMID: 27685315
DOI: 10.1080/10428194.2016.1205744

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacologic maintenance strategies following allogeneic hematopoietic cell transplantation for acute myeloid leukemia.PMID 27685315Read ↗

Maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantationSemantic proximity Read ↗

A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patientsSemantic proximity Read ↗

Hypomethylating agent-based post-transplant strategies to maximize the outcome of high-risk acute myeloid leukemia after allogeneic stem cell transplantation.Semantic proximity Read ↗

Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First RemissionSemantic proximity Read ↗

Maintenance therapy with Azacitidine for patients with myeloid malignancies after allogeneic hematopoietic stem cell transplantationSemantic proximity Read ↗

Phase II study of dual epigenetic targeting with chidamide and azacitidine in patients with high-risk acute myeloid leukemia after allo-HSCTSemantic proximity Read ↗

Post-transplant maintenance therapy in patients with FLT3-mutated acute myeloid leukemia: Real-world treatment patterns and outcomes.Semantic proximity Read ↗

Bridging to transplant and post-transplant maintenance therapy with FLT3 inhibitors in patients with relapsed or refractory FLT3 mutated acute myeloid leukemia.Semantic proximity Read ↗

Maintenance lenalidomide in combination with 5-azacitidine as post-remission therapy for acute myeloid leukaemia.Semantic proximity Read ↗

Olutasidenib (Rezlidhia) for acute myeloid leukemia.Semantic proximity Read ↗

Axatilimab in Recurrent or Refractory Chronic Graft-versus-Host DiseaseSemantic proximity Read ↗

Success of Immunosuppressive Treatments in Patients with Chronic Graft-versus-Host DiseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.